Co-investment Readiness Nextech frequently co-leads Series A rounds with top-tier investors (RA Capital, a16z Bio+Health, GV), signaling a collaborative approach that can open doors for joint fundraising or strategic partner introductions for portfolio companies.

Oncology Focus A dedicated oncology therapeutics investor with US and European reach, Nextech backs hard-to-target cancer programs and seeks value creation through portfolio companies—a fit for oncology CROs, translational platforms, and specialized manufacturing partners.

Global Deal Flow Active cross-border deal activity and recent investments from 2021 to 2026 indicate ongoing growth appetite, presenting opportunities to source deals, perform diligence partnerships, or align strategic development services for Nextech's portfolio.

Value Creation With a clear mandate to drive portfolio value, Nextech is a potential partner for services that accelerate clinical development, regulatory strategy, market access planning, and data-enabled decision making.

Regional Gateway Headquartered in Zurich with an extensive US/Europe focus, Nextech can act as a regional enabler for cross-border licensing, partnerships, and market access initiatives between Swiss/European biotech ecosystems and US investors.